Clinical trials
Dry Eye Syndromes trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Recruiting | 3 |
| Terminated | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medical University of Vienna | 24 |
| Laboratoires Thea | 2 |
| Vienna Institute for Research in Ocular Surgery | 2 |
| Amgen | 1 |
| Dompé Farmaceutici S.p.A | 1 |
| Gerhard Garhofer | 1 |
| Hospital Hietzing | 1 |
| Novaliq GmbH | 1 |
| Occyo GmbH | 1 |
| Redwood Pharma AB | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dry Eye Syndromes | 36 |
| Cataract | 2 |
| Autoimmune Diseases | 1 |
| Corneal Diseases | 1 |
| Corneal Injuries | 1 |
| Graves Ophthalmopathy | 1 |
| Keratitis | 1 |
| Keratoconjunctivitis Sicca | 1 |
| Limbal Stem Cell Deficiency | 1 |
| Meibomian Gland Dysfunction | 1 |
Trials
Showing 76 to 36 of 36. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.